Skip to main content
. 2020 May 26;27(11):3097–3116. doi: 10.1038/s41418-020-0564-6

Fig. 2. ABT-263 treatment alone or in combination with S63845 can selectively eliminate cells treated with senescence-inducing therapies.

Fig. 2

a Indicated cell lines were plated, and then exposed to 8 Gy gamma irradiation, 1, 5, or 10 nM paclitaxel, or doxorubicin, and media changed 24 h later. Five days later, cells were treated with indicated senolytic drug, and MTT assay was performed 24 h later to determine cell number. b Indicated cell lines were plated, and then treated with Nutlin-3a every other day (2.5–15 μM; total of four doses). One day after fourth dose of Nutlin-3a, cells were treated with ABT-263 (1 μM), and MTT assay was performed 24 h later to determine cell number. Each treatment group was in triplicate and individual data points are shown. Error bars indicate SEM. Nonnormalized data are shown in Supplementary Fig. 3a–b. Statistics (complete analysis available in Supplementary Table 2) used were (a, 4226 and Cal51) Student’s t test comparing two groups: control vs. ABT-263 treated, for Prolif, Doxo, IR, 1 nM, 5 nM, 10 nM paclitaxel Rx separately. (a, MDA-MB-175) ANOVA with Tukey’s posttest comparing four groups: control, ABT-263, S63845, ABT-263 + S63845, for Prolif and the indicated treatment groups separately. b Student’s t test comparing two groups: Doxo + DMSO vs. Doxo + ABT-263 treated and Nutlin-3a + DMSO vs. Nutlin-3a + ABT-263.